Sunday 11 October 2026 Export all AZN data to Excel Powerpack

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.

159.20 0.42 +0.26%
Market cap
$246.3B
P/E
23.6×
Fwd P/E
23.4×
Dividend yield
2.02%
F-score
9/9
Altman Z
6.26
Beneish M
−2.51
Dividend safety
54/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
27.86 28.74 35.44 64.79 388.33 40.64 94.08 44.68 29.73 19.94
Piotroski F-Score
9 6 7 7 5 7 6 4 3 6
P/S ratio
9.70 7.51 4.63 4.84 4.42 4.93 5.32 4.36 3.99 3.05
Altman Z-Score
6.26 4.71 2.70 2.65 1.95 2.29 2.23 1.90 1.80 1.68
Altman Z″-Score (non-manufacturers)
1.80 1.30 0.90 0.65 0.97 1.03 0.52 0.92 0.85 1.12
P/FCF ratio
64.63 54.50 30.32 26.95 37.86 40.36 49.48 26.76 26.22 20.99
Beneish M-Score
(2.51) (2.59) (2.58) (2.75) (2.20) (2.40) (2.59) (2.54) (2.48) (2.74)
P/Operating CF
243.37 139.74 89.04 89.51 116.50 72.96 94.35 43.27 89.85 35.77
Dividend Safety Score
54 — — — — — — — — —
P/B ratio
11.70 9.94 5.41 5.79 4.20 8.39 8.89 6.85 5.38 4.21
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
10.08 7.94 5.09 5.33 5.04 5.36 5.78 4.95 4.58 3.52
EV/EBITDA
30.39 25.72 17.18 25.60 24.85 17.17 21.09 15.32 15.31 11.16
EV/Operating CF
40.61 36.20 22.55 24.11 31.61 29.74 47.50 41.79 28.73 19.54
EV/FCF
67.12 57.61 33.38 29.68 43.21 43.92 53.79 30.42 30.09 24.25
Quick Ratio
0.72 0.74 0.64 0.67 0.74 0.76 0.68 0.72 0.62 0.72
Current Ratio
0.94 0.93 0.82 0.86 1.16 0.96 0.86 0.96 0.80 0.87
Net Debt/EBITDA
1.13 1.39 1.58 2.36 3.07 1.39 1.69 1.85 1.97 1.50
Debt/Assets
24.39% 27.72% 27.19% 29.31% 28.28% 29.52% 28.60% 31.51% 28.11% 26.88%
Debt/Equity
0.57 0.71 0.70 0.76 0.76 1.26 1.20 1.36 1.07 1.01
Asset Turnover
0.54 0.53 0.46 0.44 0.43 0.42 0.40 0.36 0.36 0.38
Operating CF/Net income
1.43 1.69 1.74 2.98 53.24 1.50 2.22 1.21 1.19 1.18
Capex/Depreciation
(1.00) (0.66) (0.62) (0.34) (0.24) (0.49) (0.09) 0.26 (0.05) (0.34)
Interest Coverage
8.11 5.74 5.04 2.79 0.81 3.95 2.04 2.39 2.44 3.54
ROE
22.83% 17.58% 15.63% 8.61% 0.41% 21.14% 9.32% 14.05% 18.02% 19.89%
ROA
9.38% 6.86% 6.03% 3.26% 0.13% 4.99% 2.19% 3.48% 4.77% 5.71%
ROIC
12.15% 9.77% 8.45% 3.99% 1.05% 11.86% 7.06% 7.78% 7.69% 11.12%
Return on Tangible Assets
92.38% 85.66% 152.15% 68.40% 0.87% 42.68% 26.00% 32.07% 68.48% 72.08%
Average Days of Receivables
101.50 100.11 107.98 92.60 100.54 101.28 90.50 95.52 89.90 79.33
Research and Development Expense of Revenue
24.23% 25.12% 23.87% 22.01% 26.02% 22.51% 24.85% 26.85% 25.63% 25.61%
Selling, General and Administrative Expense of Revenue
34.92% 37.97% 43.12% 42.74% 41.91% 43.93% 49.30% 46.91% 46.93% 42.34%
Intangible Assets out of Total Assets
0.52 0.56 0.57 0.61 0.59 0.49 0.53 0.56 0.60 0.63
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
(0.06) (0.09) (0.17) (0.17) (0.24) (0.24) (0.24) (0.32) (0.37) (0.46)
Graham Number
48.31 36.78 46.86 33.95 13.68 25.69 16.36 20.59 26.53 28.71
Earnings Yield
3.59% 3.48% 2.82% 1.54% 0.26% 2.46% 1.06% 2.24% 3.36% 5.02%
Free Cash Flow Yield
1.55% 1.83% 3.30% 3.71% 2.64% 2.48% 2.02% 3.74% 3.81% 4.76%
Revenue per Share
18.95 17.44 29.57 28.65 26.39 20.29 18.74 17.43 17.74 18.18
Operating CF per Share
4.70 3.83 6.68 6.34 4.21 3.66 2.28 2.07 2.83 3.28
Capex per Share
(1.86) (1.42) (2.17) (1.19) (1.13) (1.18) (0.27) 0.77 (0.13) (0.64)
Free Cash Flow per Share
2.84 2.40 4.51 5.15 3.08 2.48 2.02 2.84 2.70 2.64
Cash per Share
1.88 1.84 3.92 4.19 4.57 6.20 4.81 4.69 3.62 4.69
Shareholders Equity per Share
15.72 13.18 25.28 23.94 27.71 11.92 11.22 11.08 13.15 13.18
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
15.72 13.18 25.28 23.94 27.71 11.92 11.22 11.08 13.15 13.18
Free Cash Flow
8,819.00 7,453.00 6,990.00 7,966.00 4,363.00 3,250.00 2,622.00 3,597.00 3,417.00 3,340.00
Working Capital
(1,894.00) (2,039.00) (5,488.00) (3,700.00) 3,650.00 (763.00) (2,554.00) (701.00) (3,233.00) (1,994.00)
Capital Expenditures
(5,756.00) (4,408.00) (3,355.00) (1,842.00) (1,600.00) (1,549.00) (347.00) 979.00 (161.00) (805.00)
Net Current Asset Value
(36,632.00) (37,337.00) (36,899.00) (36,832.00) (39,832.00) (31,547.00) (31,218.00) (31,016.00) (33,562.00) (32,595.00)
EV/EBIT
43.07 42.92 28.48 62.93 178.51 27.65 48.23 32.30 27.96 16.52
Capex to Sales
0.10 0.08 0.07 0.04 0.04 0.06 0.01 (0.04) 0.01 0.04
Price to Operating Income
41.47 40.61 25.86 57.13 156.44 25.41 44.37 28.41 24.36 14.30
Other line items
Depreciation/Fixed assets
0.44 0.65 0.57 0.64 0.71 0.38 0.49 0.51 0.40 0.34
Cash ROIC
10.71% 9.88% 9.61% 11.09% 5.77% 7.48% 6.83% 9.20% 8.75% 8.48%
Accounts Receivable Turnover
3.77 3.81 3.69 4.11 4.23 3.96 4.12 3.90 4.27 3.83
Accounts Payable Turnover
0.45 0.46 0.40 0.65 0.72 0.36 0.37 0.40 0.39 0.37
Inventory Turnover
1.80 1.91 1.63 1.81 1.91 1.47 1.62 1.67 1.61 1.84
Average Days of Payables
867.79 803.34 987.73 560.86 555.79 1,087.29 1,037.44 949.55 984.01 927.63
Days of Inventory on Hand
225.08 189.10 239.45 138.42 263.63 277.18 236.83 213.71 256.55 206.47
Average Receivables
15,583.00 14,191.50 12,402.00 10,779.50 8,846.50 6,716.00 5,913.50 5,657.00 5,266.00 6,004.00
Average Payables
23,872.50 22,419.50 20,707.00 18,989.00 17,361.50 14,886.00 13,414.00 12,241.00 11,063.50 11,074.50
Average Inventory
5,922.50 5,356.00 5,061.50 6,841.00 6,503.50 3,608.50 3,041.50 2,962.50 2,684.50 2,238.50
Average Assets
109,054.50 102,577.00 98,801.00 100,923.00 86,046.00 64,053.00 61,014.00 62,002.50 62,940.00 61,291.00
Average Common Equity
44,795.00 40,018.50 38,112.00 38,172.50 27,462.50 15,117.00 14,320.00 15,343.00 16,655.50 17,589.00

Fold the line items

Columns are period end dates